This finding is reflected in other malignancies treated with PD-1 or PD-L1 inhibition, indicating that other parameters including tumor mutational burden or tumor-infiltrating lymphocytes also influence response to PD-1 or PD-L1 blockade (92, 93). This evidence concerns the gene PDCD1 and neoplasm.